BIONANO GENOMICS INC (BNGO)
US09075F3055 - Common Stock
Overall BNGO gets a fundamental rating of 2 out of 10. We evaluated BNGO against 58 industry peers in the Life Sciences Tools & Services industry. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative. BNGO is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BNGO had negative earnings in the past year.
BNGO had a negative operating cash flow in the past year.
In the past 5 years BNGO always reported negative net income.
BNGO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -108.44%, BNGO is doing worse than 96.55% of the companies in the same industry.
The Return On Equity of BNGO (-241.78%) is worse than 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.44% | ||
| ROE | -241.78% | ||
| ROIC | N/A |
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 26.49%, BNGO is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BNGO has remained more or less at the same level.
BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.68%
GM growth 5Y-0.69%
2. Health
2.1 Basic Checks
BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNGO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BNGO has been increased compared to 5 years ago.
The debt/assets ratio for BNGO is higher compared to a year ago.
2.2 Solvency
BNGO has an Altman-Z score of -5.32. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
BNGO has a worse Altman-Z score (-5.32) than 94.83% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that BNGO is not too dependend on debt financing.
BNGO's Debt to Equity ratio of 0.04 is fine compared to the rest of the industry. BNGO outperforms 63.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.32 |
ROIC/WACCN/A
WACC14.6%
2.3 Liquidity
BNGO has a Current Ratio of 1.40. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
BNGO has a Current ratio of 1.40. This is amonst the worse of the industry: BNGO underperforms 89.66% of its industry peers.
A Quick Ratio of 1.17 indicates that BNGO should not have too much problems paying its short term obligations.
BNGO's Quick ratio of 1.17 is on the low side compared to the rest of the industry. BNGO is outperformed by 82.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for BNGO have decreased strongly by -48.28% in the last year.
BNGO shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.88%.
BNGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.65% yearly.
EPS 1Y (TTM)-48.28%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.3%
Revenue 1Y (TTM)29.88%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Revenue growth Q2Q30.43%
3.2 Future
Based on estimates for the next years, BNGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.20% on average per year.
The Revenue is expected to grow by 45.44% on average over the next years. This is a very strong growth
EPS Next Y71.35%
EPS Next 2Y34.46%
EPS Next 3Y24.9%
EPS Next 5Y15.2%
Revenue Next Year7.68%
Revenue Next 2Y18.95%
Revenue Next 3Y27.35%
Revenue Next 5Y45.44%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BNGO's earnings are expected to grow with 24.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.46%
EPS Next 3Y24.9%
5. Dividend
5.1 Amount
BNGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONANO GENOMICS INC
NASDAQ:BNGO (4/29/2024, 8:59:05 AM)
0.801
+0.01 (+1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap41.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.44% | ||
| ROE | -241.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.49% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-48.28%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y71.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)29.88%
Revenue growth 3Y61.97%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y